Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Operating activities
Net loss	$ (50,528)	$ (23,240)
Adjustments to reconcile net loss to net cash used for operating activities:
Share-based compensation expense	9,402	4,983
Depreciation expense	992	281
Loss on disposal of equipment	132	0
Changes in operating assets and liabilities:
Inventory	(820)	0
Prepaid expenses and other current assets	(3,179)	(182)
Other assets	0	199
Accounts payable	(4,163)	(2,479)
Accrued clinical and other expenses	3,577	(439)
Accrued payroll and related expenses	(1,951)	(1,167)
Deferred rent	688	0
Net cash used for operating activities	(45,850)	(22,044)
Investing activities
Purchase of property and equipment	(994)	(750)
Net cash used for investing activities	(994)	(750)
Financing activities
Net proceeds from the issuance of common stock	109,809	117,480
Proceeds from the exercise of stock options for common stock	528	2,074
Net cash provided by financing activities	110,337	119,554
Net increase in cash, cash equivalents and restricted cash	63,493	96,760
Cash, cash equivalents and restricted cash at beginning of period	91,824	65,926
Cash, cash equivalents and restricted cash at end of period	155,317	162,686
Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets
Cash and cash equivalents	154,408	162,382
Restricted cash, current portion	0	304
Restricted cash, less current portion	$ 909	$ 0